ESTRO 2022 - Abstract Book

S1099

Abstract book

ESTRO 2022

18FDG PET-CT scan. Patients without evidence of metastatic disease started chemoradiation (CRT) with weekly gemcitabine. After CRT, before surgery evaluation, patients performed CT scan and 18-FDG PET-CT scan. Results Fifteen patients (39.5%) were excluded from the protocol because of the evidence of metastatic disease, and thus a total of twenty-three patients were consequently enrolled. Four patients (14.8%) had a progression of disease after induction chemotherapy. Median follow-up was 12.6 months. Nineteen patients (50%) completed CRT. Six patients (15.8%) had a progression of disease after CRT. Four patients are currently treating. Eleven patients underwent surgical radical resection (28.9%) (Fig.1). The median OS and the median PFS in patients who completed the therapeutic protocol were 15.7 months and 13 months, respectively. One-year OS, one-year PFS, one-year LPFS and one-year MPFS were 87.1%, 58.6%, 89.2% and 60%, respectively. Patients who underwent resection had a significant longer median OS compared with non-resected patients (17 months vs 13.2 months, p<0.05). The median PFS for resected patients was 14.5 months compared with 8.1 months for non-resected patients (p=0.07). For the entire cohort of patients the treatment was well tolerated. Only haematological grade 3-4 toxicities were observed.

Fig.1

Conclusion Altough the follow-up time is limited, these preliminary data of the protocol treatment show promising results for patients with borderline resectable and unresectable pancreatic cancer. The best results were observed in patients who were resectable after the end of the study protocol. The enrollment is actually ongoing.

PO-1304 Impact of blood parameters and normal tissue dose on overall survival in esophageal cancer patients

E. Troost 1 , L. Häberlein 2 , R. Bütof 3 , C. Jentsch 1 , F. Lohaus 1 , S. Makocki 1 , C. Valentini 1 , S. Löck 4

1 University Hospital Carl Gustav Carus, Radiotherapy and Radiation Oncology, Dresden, Germany; 2 Technische Universität Dresden, Faculty of Medicine, Dresden, Germany; 3 OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany; 4 German Cancer Consortium (DKTK), Partner Site Dresden, German Cancer Research Center (DKFZ), Heidelberg, Germany, Dresden, Germany Purpose or Objective Patients with locally advanced esophageal cancer are treated with neoadjuvant radiochemotherapy (RCTx) and resection. Despite technological advances, sufficient normal tissue sparing during radiation treatment planning is still challenging. The aim of this study was thus to investigate the association of the radiation dose applied to lungs and heart as well as of various blood parameters collected before and during RCTx on overall survival.